House dust mite-specific immunoglobulin E and G (HDM-specific IgE/IgG)

House dust mite-specific immunoglobulin E (IgE) and immunoglobulin G (IgG) are soluble antibodies found in the serum that recognize allergens from mites such as Dermatophagoides pteronyssinus and Dermatophagoides farinae. IgE antibodies play a central role in Type I hypersensitivity by binding to high-affinity receptors on mast cells and basophils; upon allergen exposure, these cells degranulate and release inflammatory mediators like histamine, leading to symptoms of asthma and rhinitis. Conversely, HDM-specific IgG, particularly the IgG4 subclass, is often induced during allergen immunotherapy and acts as a 'blocking antibody' to neutralize allergens before they can bind to IgE. While these antibodies are primarily used as diagnostic biomarkers to confirm sensitization and monitor the efficacy of immunotherapy, the IgE molecule itself is a major therapeutic target for monoclonal antibodies like Omalizumab. Monitoring the levels and ratios of these antibodies provides critical insight into a patient's allergic status and their clinical response to desensitization treatments.

Other names

HDM-specific IgEHDM-specific IgGAnti-house dust mite antibodiesDermatophagoides-specific antibodiessIgE to house dust mitesIgG to house dust mite

Omalizumab is a monoclonal antibody that binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade. Allergen immunotherapy (AIT) works by inducing the production of 'blocking' IgG antibodies (particularly IgG4) that compete with IgE for allergen binding, effectively preventing IgE-mediated mast cell activation.